Institute of Psychological Medicine and Clinical Neuroscience, Cardiff University and University Hospital of Wales, Cardiff, UK; Department of Neurology, University Hospital of Wales, Cardiff, UK.
Department of Respiratory Medicine, University Hospital Llandough, Llandough, UK.
Mult Scler. 2018 Nov;24(13):1779-1782. doi: 10.1177/1352458518790391. Epub 2018 Oct 11.
Despite proven efficacy of alemtuzumab in multiple sclerosis (MS), approximately 50% of individuals will develop a new autoimmune disease following treatment. To date, these have largely been antibody mediated and organ specific (primarily affecting the thyroid gland). In a retrospective case series of 187 patients from two UK specialist centres (Cardiff and Cambridge) followed up for a median of 10 years, we report three (1.6%) cases of sarcoidosis following alemtuzumab treatment of MS. This report increases the spectrum of auto-inflammatory disease following alemtuzumab and should be considered by clinicians when using this therapeutic agent for MS.
尽管阿仑单抗在多发性硬化症（MS）中的疗效已得到证实，但大约有 50%的患者在接受治疗后会患上新的自身免疫性疾病。迄今为止，这些疾病主要是抗体介导的和器官特异性的（主要影响甲状腺）。在对来自英国两个专业中心（卡迪夫和剑桥）的 187 名患者的回顾性病例系列研究中，我们报告了三例（1.6%）在 MS 接受阿仑单抗治疗后发生的结节病。该报告增加了阿仑单抗治疗后发生自身炎症性疾病的范围，临床医生在使用该治疗药物治疗 MS 时应加以考虑。
